Breast Cancer Clinical Trial

A Comparative Study of AZD9833 Versus Fulvestrant in Women With Advanced ER-Positive HER2-Negative Breast Cancer

Summary

This study is randomized, open-label, parallel-group, multicentre Phase 2 study aimed to compare the efficacy and safety of oral AZD9833 versus intramuscular (IM) fulvestrant in women with advanced breast cancer.

View Full Description

Full Description

Post-menopausal women with histologically or cytologically confirmed metastatic or loco-regionally recurrent ER-positive HER2-negative breast cancer before randomization and fulfilling all of the inclusion criteria and none of the exclusion criteria will be included.

After the screening visit and confirmation of eligibility, patients will be randomly assigned in a 1:1:1:1 ratio to receive 1 of the following 4 treatments, consisting of 4-week treatment cycles until disease progression (assessed by the Investigator as defined by Response Evaluation Criteria in Solid Tumours [RECIST] version 1.1):

AZD9833 (Dose A)
AZD9833 (Dose B)
AZD9833 (Dose C)
Fulvestrant (500 mg) During the treatment period, patients will have scheduled visits until treatment discontinuation. After the end of treatment, patients will attend 2 safety follow-up visits (at the time of treatment discontinuation and 28 days later) and will continue to be followed for survival.

As of December 2020, the Sponsor stopped enrolment to Dose C.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Post-menopausal female patients aged at least 18 years.
Metastatic or loco-regionally recurrent ER-positive HER2-negative adenocarcinoma of the breast.
Radiological or other objective evidence of progression on or after the last systemic therapy prior to starting study treatment.
Patients must have at least 1 lesion, not previously irradiated, that can be measured accurately at baseline as ≥10 mm in the longest diameter or in absence of measurable disease as defined above, at least 1 lytic or mixed (lytic+sclerotic) bone lesion.
Eastern Cooperative Oncology Group (ECOG)/World Health Organisation (WHO) performance status 0 to 1.

Prior endocrine therapy as follows:

Recurrence or progression on at least one line of endocrine therapy
No more than 1 line of endocrine therapy for advanced disease
No more than 1 line of chemotherapy for advanced disease
Prior treatment with CDK4/6 inhibitors is permitted
No prior treatment with fulvestrant, oral selective oestrogen receptor degrader (SERD), or related therapies
Inclusion criterion for the paired tumour biopsy research subgroup:

Washout from prior tamoxifen: 4 months to elapse from last tamoxifen dose to pre-dose on-study biopsy.

Exclusion Criteria:

Intervention with any of the following:

Any cytotoxic chemotherapy, investigational agents or other anti-cancer drugs for the treatment of breast cancer from a previous treatment regimen or clinical study within 14 days of the first dose of study treatment.
Use of systemic oestrogen-containing hormone replacement therapy within 6 months prior to the first dose of study treatment.
Medications or herbal supplements known to be strong inhibitors/inducers of cytochrome P450 3A4/5 and sensitive CYP2B6 substrates, and drugs which are substrates of CYP2C9 and/or CYP2C19 which have a narrow therapeutic index or inability to stop use within the washout period prior to receiving the first dose of study treatment.
Drugs that are known to prolong QT and have a known risk of torsades de pointes.
The following cardiovascular criteria: QTcF >470 ms, resting heart rate <45 bpm, clinically significant abnormalities of resting electrocardiogram, uncontrolled hypertension, symptomatic hypotension, factors that increase the risk for QTc prolongation, left ventricular ejection fraction <50%.
Radiotherapy with a limited field of radiation for palliation within 1 week of dosing, or to > 30% of bone marrow or a wide field within 4 weeks of dosing.
Major surgical procedure or significant traumatic injury.
Presence of life-threatening metastatic visceral disease or uncontrolled central nervous system metastatic disease.
Inadequate bone marrow reserve or organ function.
Refractory nausea and vomiting, uncontrolled chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of AZD9833.
History of hypersensitivity to active or inactive excipients of AZD9833 or fulvestrant.
Previous randomisation in the present study.
Women of childbearing potential.

Study is for people with:

Breast Cancer

Phase:

Phase 2

Estimated Enrollment:

240

Study ID:

NCT04214288

Recruitment Status:

Active, not recruiting

Sponsor:

AstraZeneca

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 91 Locations for this study

See Locations Near You

Research Site
Birmingham Alabama, 35205, United States
Research Site
Long Beach California, 90806, United States
Research Site
Fort Myers Florida, 33901, United States
Research Site
Saint Petersburg Florida, 33705, United States
Research Site
Lincoln Nebraska, 68506, United States
Research Site
Canton Ohio, 44710, United States
Research Site
Chattanooga Tennessee, 37404, United States
Research Site
Nashville Tennessee, 37203, United States
Research Site
Eagle River Wisconsin, 54521, United States
Research Site
Brasschaat , 2930, Belgium
Research Site
Charleroi , 6000, Belgium
Research Site
Gent , 9000, Belgium
Research Site
Haine-Saint-Paul , 7100, Belgium
Research Site
Leuven , 3000, Belgium
Research Site
Libramont-Chevigny , 6800, Belgium
Research Site
Namur , 5000, Belgium
Research Site
Greenfield Park Quebec, J4V 2, Canada
Research Site
Montreal Quebec, H1T 2, Canada
Research Site
Montreal Quebec, H3T 1, Canada
Research Site
Paris , 75005, France
Research Site
Vandoeuvre les Nancy , 54519, France
Research Site
Batumi , 6000, Georgia
Research Site
Tbilisi , '0112, Georgia
Research Site
Tbilisi , '0159, Georgia
Research Site
Tbilisi , '0186, Georgia
Research Site
Tbilisi , 0159, Georgia
Research Site
Tbilisi , 0186, Georgia
Research Site
Berlin , 10707, Germany
Research Site
Düsseldorf , 40225, Germany
Research Site
Essen , 45136, Germany
Research Site
Köln , 50937, Germany
Research Site
Budapest , 1122, Hungary
Research Site
Debrecen , 4032, Hungary
Research Site
Kaposvár , 7400, Hungary
Research Site
Kecskemét , 6000, Hungary
Research Site
Nyíregyháza , 4400, Hungary
Research Site
Pécs , 7624, Hungary
Research Site
Szeged , 6725, Hungary
Research Site
Jerusalem , 91031, Israel
Research Site
Jerusalem , 91120, Israel
Research Site
Nahariya , 22100, Israel
Research Site
Petah Tikva , 49414, Israel
Research Site
Bologna , 40138, Italy
Research Site
Catanzaro , 88100, Italy
Research Site
Meldola , 47014, Italy
Research Site
Messina , 98158, Italy
Research Site
Milano , 20121, Italy
Research Site
Milan , 20141, Italy
Research Site
Monza , 20900, Italy
Research Site
Napoli , 80131, Italy
Research Site
Roma , 00128, Italy
Research Site
Umbria , 5100, Italy
Research Site
Goyang-si , 10408, Korea, Republic of
Research Site
Incheon , 405-7, Korea, Republic of
Research Site
Bydgoszcz , 85-79, Poland
Research Site
Piła , 64-92, Poland
Research Site
Rzeszów , 35-02, Poland
Research Site
Skorzewo , 60-18, Poland
Research Site
Warszawa , 02-78, Poland
Research Site
Łódź , 93-51, Poland
Research Site
Almada , 2805-, Portugal
Research Site
Lisboa , 1400-, Portugal
Research Site
Lisboa , 1449-, Portugal
Research Site
Lisboa , 1649-, Portugal
Research Site
Lisboa , 1998-, Portugal
Research Site
Loures , 2674-, Portugal
Research Site
Porto , 4099-, Portugal
Research Site
Kazan , 42002, Russian Federation
Research Site
Krasnodar , 35004, Russian Federation
Research Site
Kursk , 30503, Russian Federation
Research Site
Moscow , 11547, Russian Federation
Research Site
Moscow , 12305, Russian Federation
Research Site
Pyatigorsk , 35750, Russian Federation
Research Site
Ryazan , 39001, Russian Federation
Research Site
Saint Petersburg , 19708, Russian Federation
Research Site
Saint-Petersburg , 19775, Russian Federation
Research Site
Volgograd , 40013, Russian Federation
Research Site
A Coruña , 15009, Spain
Research Site
Barcelona , 08035, Spain
Research Site
Barcelona , 08036, Spain
Research Site
Barcelona , 08190, Spain
Research Site
Madrid , 28033, Spain
Research Site
Madrid , 28050, Spain
Research Site
Sevilla , 41013, Spain
Research Site
Zaragoza , 50009, Spain
Research Site
Cherkasy , 18009, Ukraine
Research Site
Chernivtsі , 58013, Ukraine
Research Site
Dnipro , 49102, Ukraine
Research Site
Kyiv , 03039, Ukraine
Research Site
M. Kyiv , 02094, Ukraine
Research Site
S. Khodosivka , 08173, Ukraine
Research Site
Uzhhorod , 88000, Ukraine
Research Site
Burton-on-Trent , DE13 , United Kingdom
Research Site
Derby , DE22 , United Kingdom
Research Site
Leicester , LE1 5, United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 2

Estimated Enrollment:

240

Study ID:

NCT04214288

Recruitment Status:

Active, not recruiting

Sponsor:


AstraZeneca

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.